A number of studies demonstrated that targeting Smad3 can ameliorate the development and progression of tissue fibrosis in vivo, including experimental models of renal fibrosis, pulmonary fibrosis, and liver fibrosis [13,33,34,35,36]. The gene discussed is SMAD3; the disease is renal fibrosis.